Skip to content

The Swiss Neurodevelopmental Outcome Registry for Children With CHD

The Swiss Neurodevelopmental Outcome Registry for Children With CHD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05996211
Acronym
SwissORCHID
Enrollment
1000
Registered
2023-08-18
Start date
2019-01-01
Completion date
2032-12-31
Last updated
2023-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease, Congenital Heart Disease, Intensive Care Neurological Disorder, Neurodevelopmental Abnormality

Brief summary

Introduction: Congenital heart disease (CHD) is the most frequent birth defect. As survival has significantly improved, attention has turned to neurodevelopmental outcomes of children undergoing heart surgery in early infancy. Since multiple risk factors contribute to neurodevelopmental alterations, a nationwide registry collecting data on medical characteristics, interventions, clinical course and neurodevelopment until school-age is needed to improve the quality of management, identify risk- and protective factors affecting neurodevelopment, and facilitate multicenter trials. Methods and analysis: The Swiss Outcome Registry for CHIldren with severe congenital heart Disease (ORCHID) is a nationwide, prospective, population-based patient registry developed (1) to collect baseline characteristics and clinical data of CHD patients operated with bypass-surgery or hybrid procedures in the first 6 weeks of life in Switzerland, (2) to monitor long-term neurodevelopment, and (3) to relate clinical characteristics and neurodevelopment to identify risk and protective factors in these children. This registry started data collection relating to pregnancy, birth, preoperative course, catheter-based and surgical treatment, postoperative course and reinterventions in 2019. The primary outcome includes standardised neurodevelopmental assessments at 9 to 12 months, 18 to 24 months and 5.5 to 6 years. Investigators expect to include 80 to 100 children per year. Correlation and regression analyses will be used to investigate risk- and protective factors influencing neurodevelopment. Ethics and dissemination of results: Swiss ORCHID received support by the Accentus Charitable Foundation, the Anna Mueller Grocholoski Foundation, the Swiss Society of Pediatric Cardiology, and the Corelina - Foundation and was approved by the cantonal ethics committees. Findings will be presented at national and international scientific meetings, and published in peer-reviewed journals. Results will also be shared with patient organizations, primary health care providers, and public health stakeholders to ensure a widespread dissemination of the results.

Interventions

None listed

Sponsors

University of Lausanne Hospitals
CollaboratorOTHER
University of Geneva, Switzerland
CollaboratorOTHER
University of Bern
CollaboratorOTHER
University Children's Hospital, Zurich
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Weeks to 6 Weeks
Healthy volunteers
No

Inclusion criteria

* Neonates (including preterm born children) with severe CHD * Requiring an invasive cardiac intervention (including heart-lung-machine) within the first 6 weeks of life.

Exclusion criteria

* Neonates (including preterm born children) with simple CHD * Requiring simple cardiac surgery or catheter intervention such as closure of patent arterial duct or simple repair of aortic coarctation without heart-lung-machine and low impact on neurodevelopmental outcome.

Design outcomes

Primary

MeasureTime frameDescription
Bayley scales of infant and toddler development III at one year of ageOne year of ageNeurodevelopmental outcome measurement at one year of age (normal value 100, higher values mean better outcome)
Bayley scales of infant and toddler development III at two years of ageTwo years of ageNeurodevelopmental outcome measurement at two years of age (normal value 100, higher values mean better outcome)
Bayley scales of infant and toddler development III at five years of ageFive years of ageNeurodevelopmental outcome measurement at five years of age (normal value 100, higher values mean better outcome)

Countries

Switzerland

Contacts

Primary ContactWalter Knirsch, MD
walter.knirsch@kispi.uzh.ch+41 44 266 7111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 28, 2026